The Indian stock market is buzzing with activity again, and this time, all eyes are on the pharmaceutical sector. Corona Remedies Limited, a fast-growing homegrown pharma company, has launched its Initial Public Offering (IPO) today, December 8, 2025.
If you are an investor looking for the next big opportunity, you might be asking: What is the Grey Market Premium (GMP)? Is the price too high? Should I invest my money?
In this detailed guide, we will break down the Corona Remedies IPO GMP, analyze the company’s financial health, and help you decide if this IPO deserves a spot in your portfolio.
1. Corona Remedies IPO GMP Today (Live Update)
Let’s get straight to the numbers. The Grey Market Premium (GMP) is often the first indicator of how popular an IPO is among investors. It tells us the “unofficial” price people are willing to pay before the shares are even listed.
As of Monday, December 8, 2025, the market sentiment looks positive.
• IPO Price Band: ₹1,008 to ₹1,062 per share
• Current GMP: ~₹290 per share
• Estimated Listing Price: ₹1,352 (approx.)
• Expected Listing Gain: ~27%
What does this mean?
A 27% premium indicates that investors are quite excited about this issue. If you are allotted shares, you could potentially see a profit of around ₹290 per share on the listing day itself, assuming the market conditions remain stable. However, remember that GMP is not official and can change rapidly.
2. Corona Remedies IPO Details: The Quick Snapshot
Before you hit that “Apply” button, you need to know the basics. This IPO is an Offer For Sale (OFS), which means the money raised will go to existing shareholders (like promoters and investors) rather than into the company’s bank account for expansion.
• IPO Open Date: December 8, 2025 (Today)
• IPO Close Date: December 10, 2025
• Price Band: ₹1,008 – ₹1,062 per share
• Lot Size: 14 Shares
• Minimum Investment (Retail): ₹14,868
• Total Issue Size: ₹655.37 Crores
• Listing Date (Tentative): December 15, 2025
3. What Does Corona Remedies Do? (Business Model)
You should never invest in a business you don’t understand. Fortunately, Corona Remedies is easy to grasp.
Founded in 2004, Corona Remedies is an India-focused pharmaceutical company. Unlike some pharma giants that export heavily to the US or Europe, Corona focuses on the domestic Indian market. They manufacture and sell medicines that you might find at your local pharmacy.
Key Strengths:
• Women’s Health & Cardio: They are strong leaders in women’s healthcare, cardiology (heart), and pain management.
• Power Brands: They own popular brands like B-29 and Myoril.
• Doctor Network: They have a massive network of over 2,600 medical representatives who market their products directly to specialists and doctors across 22 states.
• Manufacturing: They operate modern manufacturing facilities in Gujarat.
Why is this good?
Focusing on the Indian market shields them from the strict regulatory headaches often faced by companies exporting to the US (like USFDA bans).
Are you subscribing to the Corona Remedies IPO?
— Vishnu Agarwal (@vishnuagarwal64) December 6, 2025
Most of the Indian Pharma Market is struggling for single-digit growth. Corona Remedies is a statistical outlier, clocking 16.77% CAGR — growing 1.8x faster than the industry average.
They focus on high-margin chronic therapies,… pic.twitter.com/DiADcuibgJ
4. Financial Health: Is the Company Making Money?
A pretty logo doesn’t pay the bills—profits do. Let’s look at their financial scorecard for the Financial Year 2025 (FY25).
• Revenue: ₹1,202 Crores (Up 18%)
• Net Profit (PAT): ₹149 Crores ( surged significantly!)
• Debt: Very low (Debt-to-Equity ratio is just 0.10)
The company is growing faster than many of its competitors in the Indian market. Their ability to increase profits by 65% in the last year alone is a major green flag for investors.
5. The Risks: What Could Go Wrong?
No investment is risk-free. Here are the red flags you should consider:
• Valuation: The Price-to-Earnings (P/E) ratio is around 43x. This is slightly expensive compared to some peers, meaning the share price is already reflecting a lot of the future growth.
• Offer For Sale (OFS): As mentioned earlier, all the money from this IPO goes to the selling shareholders, not to the company. The company won’t have fresh cash to build new factories or buy new technology from this IPO.
• Dependency: A large chunk of their revenue comes from just a few top brands. If a competitor launches a better version of their top-selling medicine, their sales could take a hit.
6. Corona Remedies IPO Review: Subscribe or Avoid?
So, the million-dollar question: Should you apply?
✅ The Bull Case (Why Apply):
If you are looking for listing gains, the current GMP of ~27% is attractive. The company has strong fundamentals, a clean balance sheet with low debt, and operates in the high-growth Indian pharma sector. For long-term investors, the focus on “lifestyle diseases” (heart, diabetes, women’s health) is a great theme for the next decade.
❌ The Bear Case (Why Avoid):
If you are a strictly value-conscious investor, you might find the price band of ₹1,062 a bit steep. Since it is purely an OFS, some investors prefer companies that are raising fresh capital for growth.
Verdict:
Most financial experts suggest a SUBSCRIBE rating for this IPO, primarily due to its strong domestic foothold and healthy financial growth. It looks good for both listing gains and potentially long-term holding.
7. How to Check Allotment Status
Once you apply, the waiting game begins. The allotment is expected to be finalized on Thursday, December 11, 2025.
You can check your status on:
1. BSE Website: Under “Equity” > Select “Corona Remedies Limited”.
2. Registrar Website (Bigshare Services): Enter your PAN card number to see if you got lucky!
Final Thoughts
The Corona Remedies IPO arrives at a time when the market is hungry for quality pharma stocks. With a healthy GMP and solid business numbers, it ticks many right boxes. However, always invest what you can afford to lose and consult your financial advisor before making a decision.
Are you applying for this IPO? Let us know in the comments below!
FAQs
1. What is the official listing date for Corona Remedies IPO?
The shares are tentatively scheduled to list on the stock exchanges (BSE & NSE) on Monday, December 15, 2025.
2. What is the minimum amount required to apply?
Retail investors need a minimum of ₹14,868 to apply for one lot (14 shares).
3. Is Corona Remedies a debt-free company?
While not 100% debt-free, they have very low debt (0.10 ratio), which is considered extremely healthy in the financial world.